News A deep learning pipeline for controlling protein interactionsPublished:16.01.25 — EPFL scientists have used deep learning to design new proteins that bind to complexes involving other small molecules like hormones or drugs, opening up a world of possibilities in the computational design of molecular interactions for biomedicine.A new drug for muscle agingPublished:15.01.25 — Scientists at EPFL have developed ALT-007, a safe, oral compound that restores muscle mass and function in aging mice, potentially offering a novel treatment for age-related muscle loss and neuromuscular diseases.GenAI ushers in a new era of drug researchPublished:15.01.25 — The use of generative artificial intelligence in protein design stands to revolutionize new drug development. EPFL ambitions putting together a consortium to further explore this avenue.Li Tang wins Friedrich Miescher AwardPublished:09.01.25 — School of Engineering Professor Li Tang has won one of the two Friedrich Miescher Awards for 2025 for his outstanding achievements in biochemistry.New cancer models could help personalize lymphoma treatmentsPublished:18.12.24 — Scientists at EPFL have developed "lymphomoids," a pioneering cancer model that preserves the structure and multicellular composition of lymphoma tumors in the lab. Lymphomoids offer an innovative way to test the efficacy of lymphoma treatments and better predict individual responses.
